Pipeline

Advanced medicines that demonstrate both strong clinical performance and benefits to patients.

Pipeline
90
+
compounds, devices or indications in development individually or under collaboration or license agreement
investment
$7.8
b
R&D investment in 2023
Commitment
50
+
programs are in mid and late-stage development
Novel
80
%
of compounds in clinical development with a novel mechanism of action

Pipeline

Updated November 15, 2024

Sort By 
Focus Area
Molecule/Asset Phase
Molecule/Asset Type
Device Asset Phase
Device Asset Type
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hidradenitis Suppurativa
N ∕ A
N ∕ A phase3
phase3
Ulcerative Colitis
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Small Cell Lung Cancer
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ovarian Cancer
N ∕ A
N ∕ A phase1
phase1
Endometrial Cancer
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
mCRPC
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
BPDCN
N ∕ A
N ∕ A phase2
phase2
Acute Myeloid Leukemia
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Acute Myeloid Leukemia
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Multiple Myeloma
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hypothyroidism
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Complicated Gram-negative Infections
N ∕ A
N ∕ A
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Systemic Lupus Erythematosus (SLE)
Global
Global phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alzheimer's Disease
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alzheimer's Disease
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Advanced Pancreatic Cancer
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Open Angle Glaucoma
N ∕ A
N ∕ A phase2
phase2
Ocular Hypertension
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ulcerative Colitis
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Systemic Lupus Erythematosus (SLE)
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
IBD
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
wet AMD (subretinal)
N ∕ A
N ∕ A phase3
phase3
wet AMD (suprachoroidal)
N ∕ A
N ∕ A phase2
phase2
Diabetic Retinopathy (suprachoroidal)
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Hematologic Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Glabellar Lines
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Atopic Dermatitis
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Relapsed ∕ Refractory Diffuse Large B-cell Lymphoma
US , EU
US , EU approved
approved
Relapsed ∕ Refractory Follicular Lymphoma
N ∕ A
N ∕ A approved
approved
First Line Follicular Lymphoma
N ∕ A
N ∕ A phase3
phase3
First Line Large B-cell Lymphoma
US , EU
US , EU phase3
phase3
B-cell Non-Hodgkin lymphoma
N ∕ A
N ∕ A phase2
phase2
Relapsed ∕ Refractory Chronic Lymphocytic Leukemia
N ∕ A
N ∕ A phase1
phase1
Richter's Syndrome
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Spinal Cord Injury
N ∕ A
N ∕ A phase2
phase2
Acute Ischemic Stroke
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Bipolar Depression
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
HIV
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Parkinson's Disease
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Ulcerative Colitis
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
IBD
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Schizophrenia
N ∕ A
N ∕ A phase2
phase2
Alzheimer's Disease Psychosis
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Parkinson's Disease
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Dementia-related Apathy
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Major Depressive Disorder
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Crohn's Disease
US , EU
US , EU approved
approved
Psoriasis
US , EU
US , EU approved
approved
Psoriatic Arthritis
US , EU
US , EU approved
approved
Ulcerative Colitis
US , EU
US , EU approved
approved
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Liver
N ∕ A
N ∕ A phase2
phase2
Solid Tumors
N ∕ A
N ∕ A phase2
phase2
Non-Small Cell Lung Cancer
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Multiple Myeloma
N ∕ A
N ∕ A phase3
phase3
Immunoglobulin Light Chain (AL) Amyloidosis
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Non-Small Cell Lung Cancer
N ∕ A
N ∕ A
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Colorectal Cancer
N ∕ A
N ∕ A phase2
phase2
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Amyotrophic Lateral Sclerosis (ALS)
N ∕ A
N ∕ A phase2
phase2
Vanishing White Matter disease (VWM)
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Acute Myeloid Leukemia
US , EU
US , EU approved
approved
Acute Myeloid Leukemia post transplant
N ∕ A
N ∕ A phase3
phase3
Chronic Lymphocytic Leukemia with 17p deletion
US , EU
US , EU approved
approved
First-line Chronic Lymphocytic Leukemia
US , EU
US , EU approved
approved
Myelodysplastic Syndrome
US , EU
US , EU phase3
phase3
Relapsed ∕ Refractory Chronic Lymphocytic Leukemia
US , EU
US , EU approved
approved
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Solid Tumors
N ∕ A
N ∕ A phase1
phase1
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Parkinson's Disease
US , JA , EU
US , JA , EU approved
approved
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Panic Disorder
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Episodic Migraine Prophylaxis
N ∕ A
N ∕ A phase3
phase3
Essential Tremor
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
IC BPS
N ∕ A
N ∕ A phase2
phase2
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Platysma Prominence
US
US approved
approved
Masseter Prominence
CN N ∕ A
CN approved
N ∕ A phase3
approved
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Alopecia Areata
N ∕ A
N ∕ A phase3
phase3
Ankylosing Spondylitis
US , EU
US , EU approved
approved
Atopic Dermatitis
US , EU
US , EU approved
approved
Axial SpA
US , EU
US , EU approved
approved
Crohn's Disease
US , EU
US , EU approved
approved
Giant Cell Arteritis
US , EU
US , EU
Hidradenitis Suppurativa
N ∕ A
N ∕ A phase3
phase3
Psoriatic Arthritis
US , EU
US , EU approved
approved
Rheumatoid Arthritis
US , EU
US , EU approved
approved
Systemic Lupus Erythematosus (SLE)
N ∕ A
N ∕ A phase3
phase3
Takayasu Arteritis
JA
JA phase3
phase3
Ulcerative Colitis
US , EU
US , EU approved
approved
Vitiligo
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Phase 1 Phase 2 Phase 3 Status
Status
Platinum-Resistant Ovarian Cancer
N ∕ A
N ∕ A approved
approved
Platinum-Sensitive Ovarian Cancer
N ∕ A
N ∕ A phase3
phase3
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Atrophic Scars
N A
N A confirmation
confirmation
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Cellulite
N A
N A development
development
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Facial Volume
N A
N A confirmation
confirmation
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Temple Augmentation
US
US approved
approved
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Fine Line Reduction
US , EU , JA
US , EU , JA approved
approved
Neck Line Reduction
N A
N A confirmation
confirmation
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Facial Volume
EU N A
EU approved
N A development
approved
development
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Infraorbital Hollowing
US
US approved
approved
Potential Indication
Region
Feasibility Development Confirmation Status
Status
Jawline Definition
US
US approved
approved
No Results Found Change your filter or search criteria.